What is the new medicine for vasculitis? Latest targeted treatments explained
•
3 min read
For decades, vasculitis treatment relied heavily on broad immunosuppressants, often with severe side effects from long-term steroid use. In recent years, newer, more targeted medicines like avacopan for ANCA-associated vasculitis and benralizumab for EGPA have revolutionized therapy by offering a steroid-sparing approach. These advances provide hope for a future with more personalized and effective treatments and better quality of life for patients.
